myelodysplastic syndromes (MDS) | Page 105 | Aplastic Anemia and MDS International Foundation

myelodysplastic syndromes (MDS)

Transplantation strategies for the management of patients with myelodysplastic syndromes.

Author(s): 
Meletis J, Terpos E
Primary Author: 
Meletis J
Journal Title: 
J BUON
Original Publication Date: 
Oct 2009

Allogeneic stem cell transplantation (SCT) is the only therapeutic modality at present that may be delivered with curative intent in

Bone Marrow Diseases: 

Novel approaches for myelodysplastic syndromes: beyond hypomethylating agents.

Author(s): 
Loaiza-Bonilla A, Gore SD, Carraway HE
Primary Author: 
Loaiza-Bonilla A
Journal Title: 
Curr Opin Hematol
Original Publication Date: 
Mar 2010

PURPOSE OF REVIEW:

Several novel therapeutic approaches exist for treatment of patients with myelodysplastic syndrome, with goals to improve quality of life and prolong survival. This review highlights new therapies from the last 18 months.

Bone Marrow Diseases: 

The genetic basis of myelodysplastic syndromes.

Author(s): 
Bejar R, Ebert BL
Primary Author: 
Bejar R
Journal Title: 
Hematol Oncol Clin North Am
Original Publication Date: 
Apr 2010

Myelodysplastic syndrome (MDS) disorders are clonal diseases that often carry stereotypic chromosomal abnormalities. A smaller proportion of cases harbor point mutations that activate oncogenes or inactivate tumor suppressor genes. New technologies have accelerated the pace of discovery and are responsible for the identification of novel genetic mutations associated with MDS and other myeloid neoplasms. These discoveries have identified novel mechanisms in the pathogenesis of MDS. This article touches on the better known genetic abnormalities in MDS

Bone Marrow Diseases: